Volume 18, Number 1—January 2012
Research
Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs
Michael L. Jackson1
, Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy
, Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy
Figure 2
Figure 2. Observed and simulated incidence of invasive Haemophilus influenzae type b in children <5 years of age in 3 populations: (A) United States; (B) England and Wales; (C) Alaska Natives. PRP-OMP, Hib polyribosylribitol phosphate polysaccharide conjugated to Neisseria meningitidis outer membrane protein; HbOC, Haemophilus b conjugate vaccine; PRP-T, polyribosylribitol phosphate polysaccharide conjugated to tetanus toxoid.
1Current affiliation: Group Health Research Institute, Seattle, Washington, USA.
Page created: December 21, 2011
Page updated: December 21, 2011
Page reviewed: December 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.